Nephrogenic Systemic Fibrosis
10 Years of Nephrogenic Systemic Fibrosis (NSF)
What Conclusions Can Be Drawn From Report Numbers?
U.S. annual GBCA administrations (lines, right ordinate) and U.S. Magnevist® confirmed NSF reports (single agent Cowper / Girardi positive, n=68) (columns, left ordinate). The vertical dotted line indicates the introduction of the Box Warning by the FDA, May 2007, after which the number of reports drastically slumped. Through 2006 Magnevist® and Omniscan™ had > 80% combined market share. Primovist®, Gadovist® and Dotarem® entered the U.S. market only in 2008, 2011 and 2013.